In total, 9,000,000 warrants have been subscribed, 3,000,000 by the management excluding the Executive Vice
Chairman, and 6,000,000 were subscribed by the Board of Directors, excluding owners controlling more than ten percent of the shares
or votes in the Company. The Chairman of the Board of Directors subscribed for 4,000,000 warrants. The share capital will, in case
of full utilization, increase with SEK 900,000.
This information has been published in accordance with Chapter 4, 9 § in the Financial Instruments Tradings
Act.
Notes to editors:
About Oasmia Pharmaceutical AB
Oasmia Pharmaceutical AB develops, manufactures, markets and sells new generations of drugs in the field of human
and veterinary oncology. The company’s product development aims to create and manufacture novel nanoparticle formulations and
drug-delivery systems based on well-established cytostatics which, in comparison with current alternatives, show improved
properties, reduced side-effects, and expanded applications. The company’s product development is based on its proprietary in-house
research and company patents. Oasmia is listed on NASDAQ Capital Markets (OASM.US), Frankfurt Stock Exchange (OMAX.GR, ISIN
SE0000722365) and NASDAQ Stockholm (OASM.ST).
IMPORTANT INFORMATION
Issuance, publication or distribution of this press release in certain jurisdictions could be
subject to restrictions. The recipient of this press release is responsible for using this press release and the constituent
information in accordance with the rules and regulations prevailing in the particular jurisdiction. This press release does not
constitute an offer or an offering to acquire or subscribe for any Oasmia Pharmaceutical AB (publ) securities in any jurisdiction,
neither from Oasmia Pharmaceutical AB (publ) nor anyone else.
Attachments:
http://www.globenewswire.com/NewsRoom/AttachmentNg/351111e9-846f-46a6-9dd0-3b76ee21f189
Fredrik Gynnerstedt, CFO Tel: +46 18 50 54 40 E-mail: fredrik.gynnerstedt@oasmia.com
